FGF23 and hypercalcemia disease: In humans, loss-of-function mutations in FGF23 or αKLOTHO are associated with elevated circulating 1,25(OH)2D levels and subsequent hypercalcemia and hyperphosphatemia, leading to progressive soft tissue calcifications [73,74,75].